NO20082425L - Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer - Google Patents

Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer

Info

Publication number
NO20082425L
NO20082425L NO20082425A NO20082425A NO20082425L NO 20082425 L NO20082425 L NO 20082425L NO 20082425 A NO20082425 A NO 20082425A NO 20082425 A NO20082425 A NO 20082425A NO 20082425 L NO20082425 L NO 20082425L
Authority
NO
Norway
Prior art keywords
formulations
jorumycin
safracin
saframycin
related compounds
Prior art date
Application number
NO20082425A
Other languages
English (en)
Other versions
NO341057B1 (no
Inventor
Salve Pilar Calvo
Maria Tobio Barreira
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20082425L publication Critical patent/NO20082425L/no
Publication of NO341057B1 publication Critical patent/NO341057B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Jorumycin-, renieramycin-, safracin- og saframycinrelaterte forbindelsesformuleringer, fremgangsmåter for fremstilling av disse, fremstillingsartikler og sett med slike- formuleringer, og metoder for behandling av proliferative sykdommer med de samme formuleringer er tilveiebrakt.
NO20082425A 2005-10-31 2008-05-30 Farmasøytisk sammensetning, som omfatter et disakkarid og en jorumycin-, renieramycin-, safracin- eller saframycin-beslektet forbindelse, fremgangsmåte for fremstilling av en ampulle inneholdende en lyofilisert formulering derav, fremgangsmåte for redusering av dannelsen av urenheter i formuleringen, fremgangsmåte for fremstilling av en løsning derav for intravenøs infusjon, anvendelse derav ved fremstilling av et medikament for behandling av kreft. NO341057B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0522082.7A GB0522082D0 (en) 2005-10-31 2005-10-31 Formulations
PCT/GB2006/050362 WO2007052076A2 (en) 2005-10-31 2006-10-30 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Publications (2)

Publication Number Publication Date
NO20082425L true NO20082425L (no) 2008-07-25
NO341057B1 NO341057B1 (no) 2017-08-14

Family

ID=35515969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082425A NO341057B1 (no) 2005-10-31 2008-05-30 Farmasøytisk sammensetning, som omfatter et disakkarid og en jorumycin-, renieramycin-, safracin- eller saframycin-beslektet forbindelse, fremgangsmåte for fremstilling av en ampulle inneholdende en lyofilisert formulering derav, fremgangsmåte for redusering av dannelsen av urenheter i formuleringen, fremgangsmåte for fremstilling av en løsning derav for intravenøs infusjon, anvendelse derav ved fremstilling av et medikament for behandling av kreft.

Country Status (24)

Country Link
US (1) US9192568B2 (no)
EP (1) EP1968592B1 (no)
JP (1) JP5197373B2 (no)
KR (1) KR101434230B1 (no)
CN (1) CN101300011B (no)
AT (1) ATE549023T1 (no)
AU (1) AU2006310260C1 (no)
CA (1) CA2625096C (no)
DK (1) DK1968592T3 (no)
ES (1) ES2383967T3 (no)
GB (1) GB0522082D0 (no)
HK (1) HK1122743A1 (no)
HR (1) HRP20120478T1 (no)
IL (1) IL190774A (no)
NO (1) NO341057B1 (no)
NZ (1) NZ567291A (no)
PL (1) PL1968592T3 (no)
PT (1) PT1968592E (no)
RS (1) RS52312B (no)
RU (1) RU2429845C2 (no)
SI (1) SI1968592T1 (no)
UA (1) UA97629C2 (no)
WO (1) WO2007052076A2 (no)
ZA (1) ZA200803420B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
CN102065865B (zh) * 2008-05-16 2013-03-20 马尔药品公司 多发性骨髓瘤治疗
RU2010151602A (ru) * 2008-05-16 2012-06-27 Фарма Мар, С.А. (Es) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
PL2701720T3 (pl) 2011-04-28 2017-12-29 Oncopeptides Ab Liofilizowany preparat cytotoksycznych dipeptydów
SI2928463T1 (sl) 2012-10-26 2020-03-31 Oncopeptides Ab Liofilizirani pripravki melfalan flufenamida
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
EP3655379B1 (en) 2017-07-19 2023-04-05 California Institute of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
EP4303221A1 (en) * 2021-03-03 2024-01-10 The University of Tokyo Novel tetrahydroisoquinoline alkaloid compound containing macrocycle

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
DE19605212A1 (de) * 1996-02-13 1997-08-14 Basf Ag Phosphordotiertes Silberkatalysator-Festbett
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AU7589898A (en) 1997-05-21 1998-12-11 Genentech Inc. Novel administration of thrombopoietin
CA2327468C (en) 1998-04-06 2008-05-06 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
US6316214B1 (en) 1998-05-11 2001-11-13 The Board Of Trustees Of The University Of Illinois ETM-775 metabolite of ecteinascidin 743
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en) 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
ATE314084T1 (de) * 2000-10-31 2006-01-15 Pharma Mar Sa Kahalalid f formulierung
CA2447553A1 (en) * 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
NZ525730A (en) 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
HUP0302567A2 (hu) 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
WO2002076459A1 (en) 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
US20030027799A1 (en) 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
BR0213424A (pt) 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7251892B2 (en) * 2003-07-09 2007-08-07 Temper Corporation Bearing assembly spacer adjustable system and method for adjusting a spacer
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
AU2004291037A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
EP1768671A2 (en) 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
CN101119750B (zh) 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
PL1658848T3 (pl) * 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
WO2007062413A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
GB0522082D0 (en) 2005-12-07
JP5197373B2 (ja) 2013-05-15
AU2006310260B2 (en) 2012-08-09
KR20080064959A (ko) 2008-07-10
IL190774A0 (en) 2008-11-03
RU2008121716A (ru) 2009-12-10
US20090076016A1 (en) 2009-03-19
ES2383967T3 (es) 2012-06-27
RU2429845C2 (ru) 2011-09-27
AU2006310260C1 (en) 2013-09-19
UA97629C2 (ru) 2012-03-12
NZ567291A (en) 2011-04-29
CN101300011A (zh) 2008-11-05
EP1968592A2 (en) 2008-09-17
IL190774A (en) 2013-11-28
CA2625096C (en) 2015-11-24
PT1968592E (pt) 2012-06-18
WO2007052076A3 (en) 2008-03-20
NO341057B1 (no) 2017-08-14
EP1968592B1 (en) 2012-03-14
WO2007052076A2 (en) 2007-05-10
CN101300011B (zh) 2011-12-28
US9192568B2 (en) 2015-11-24
HK1122743A1 (en) 2009-07-17
AU2006310260A1 (en) 2007-05-10
ATE549023T1 (de) 2012-03-15
KR101434230B1 (ko) 2014-08-26
RS52312B (en) 2012-12-31
SI1968592T1 (sl) 2012-10-30
CA2625096A1 (en) 2007-05-10
HRP20120478T1 (hr) 2012-07-31
JP2009513618A (ja) 2009-04-02
PL1968592T3 (pl) 2012-08-31
ZA200803420B (en) 2009-10-28
DK1968592T3 (da) 2012-07-02

Similar Documents

Publication Publication Date Title
TW200621256A (en) Formulations
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
WO2009105513A8 (en) Novel compounds and methods for therapy
NO20070782L (no) Tetrapeptidanaloger.
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
EA200802332A1 (ru) Пирролопиримидины и их применение
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
WO2007047608A3 (en) Fibrin targeted therapeutics
WO2007097981A3 (en) Alpha carbolines and uses thereof
WO2007120333A3 (en) Tetracyclic kinase inhibitors
WO2006109301A3 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
ATE433459T1 (de) Desoxo-nonadepsipeptide
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
GB0515025D0 (en) Organic compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees